文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗联合纳武利尤单抗治疗晚期黑色素瘤的真实世界结局:一项多中心回顾性研究

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
PubMed 文献 · Eur J Cancer · 2022-10-07

这项多中心回顾性研究纳入2015年10月至2020年1月在澳大利亚、欧洲和美国六中心接受伊匹木单抗联合纳武利尤单抗治疗的晚期黑色素瘤患者697例,评估疗效与毒性。中位随访25.9个月,初治无脑转移患者中位OS为53.7个月,初治有脑转移者为38.7个月,全队列ORR为48%,3-4级治疗相关不良事件发生率为44%,治疗相关死亡4例(0.7%)。

要点

  • 初治无脑转移患者中位OS为53.7个月,初治有脑转移患者为38.7个月。
  • 全队列ORR为48%,初治无脑转移患者ORR为56.6%,中位PFS为13.7个月。
  • 3-4级治疗相关不良事件发生率为44%,治疗相关死亡4例(0.7%)。

核心结论

  • 在真实世界患者人群中,伊匹木单抗联合纳武利尤单抗的结局和毒性与关键试验报告的结果相似。

研究设计与样本

  • 多中心回顾性分析,纳入2015年10月至2020年1月在澳大利亚、欧洲和美国六中心接受伊匹木单抗联合纳武利尤单抗治疗的晚期黑色素瘤患者697例。
  • 初治患者472例,其中138例(29.2%)有脑转移;经治患者225例,其中102例(45.3%)有脑转移。
  • 基线时32.3%为M1c期,34.4%为M1d期;乳酸脱氢酶升高者280例(40.2%)。

主要发现

  • 中位随访25.9个月,初治无脑转移的334例患者中位OS为53.7个月(95%CI 40.8-NR),初治有脑转移的138例患者中位OS为38.7个月(95%CI 18.6-NR)。
  • 全队列ORR为48%,初治无脑转移患者ORR为56.6%,中位PFS为13.7个月(95%CI 9.6-26.5)。
  • 全队列中位PFS为7.9个月(95%CI 5.8-10.4),中位OS为38个月(95%CI 31-NR)。
  • 3-4级治疗相关不良事件发生率为44%,治疗相关死亡4例(0.7%),包括肺炎1例、心肌炎2例和结肠炎1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess efficacy and toxicity of combination immunotherapy with ipilimumab plus nivolumab in routine practice in a retrospective multicentre cohort of patients with advanced melanoma. PATIENTS AND METHODS: This retrospective analysis included patients with advanced melanoma treated with ipilimumab and nivolumab between October 2015 and January 2020 at six centres in Australia, Europe and the United States of America. We describe efficacy outcomes (overall survival [OS], progression-free survival [PFS] and objective response rate [ORR]) in treatment-naïve and pre-treated patients, with and without brain metastases, plus treatment-related adverse events (trAEs) in all patients treated. RESULTS: A total of 697 patients were identified; 472 were treatment-naïve of which 138 (29.2%) had brain metastases, and 225 were previously treated of which 102 (45.3%) had brain metastases. At baseline, 32.3% had stage M1c and 34.4% stage M1d disease. Lactate dehydrogenase was high in 280 patients (40.2%). With a median follow-up of 25.9 months, median OS in the 334 treatment-naïve patients without brain metastases was 53.7 months (95% confidence interval [CI] 40.8-NR) and 38.7 months (95% CI 18.6-NR) for the 138 treatment-naïve patients with brain metastases. For the entire cohort the ORR was 48%, for treatment-naïve patients without brain metastases ORR was 56.6% with a median PFS of was 13.7 months (95% CI 9.6-26.5). Median PFS was 7.9 months (95% CI 5.8-10.4) and OS 38 months (95% CI 31-NR) for the entire cohort. Grade 3-4 trAE were reported in 44% of patients, and 4 (0.7%) treatment-related deaths (1 pneumonitis, 2 myocarditis and 1 colitis) were recorded. CONCLUSION: The outcome and toxicity of combination immunotherapy with ipilimumab and nivolumab in a real-world patient population are similar to those reported in pivotal trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Serra-Bellver P, Versluis JM, Oberoi HK, et al. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur J Cancer. 2022. PMID: 36215945. doi:10.1016/j.ejca.2022.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。